Seemingly disappointing, the Bcr-Abl kinase inhibitor STI-571 shares an 'unfortunate' characteristic with conventional cancer drugs: the development of drug resistance. I argue that the resistance must develop even faster to STI-571 than to conventional drugs, because STI-571 is so effective. This is predictable, but is it inevitable? And how do mechanisms of resistance in relapse depend on a degree of remission. In addition to mutation rate and number of tumor cells, one additional factor determines relapse vs 'extinction' of the leukemia cell population.
'Unfortunate' characteristic of STI-571
STI-571 is an inhibitor of the Bcr-Abl oncogene kinase. 1 This kinase is etiologic for adult chronic myeloid leukemia (CML) and blast crisis as well as a fraction of acute lymphoblastic leukemias. 2 As a product of the fusion gene which is absent in normal cells, Bcr-Abl represents an ideal therapeutic target. In fact, therapy with STI-571 which inhibits the Abl kinase induces remissions. Furthermore, adverse effects of STI-571 are minimal. Complete hematologic responses were observed in 53 of 54 patients with CML and typically occurred in the first 4 weeks of therapy. 3 Also, responses occurred in 55% of patients with a myeloid blast crisis. 4 Disappointingly, however, the remissions in blast crisis patients usually last only 2-6 months. Despite continuous therapy, relapses occur due to an acquired drug resistance. A recent report in Science by Gorre et al 5 indicates that amplifications and mutations in Bcr-Abl renders cells resistant to STI-571. As stated by Jean Marx 'STI-571 shares an unfortunate characteristic with conventional cancer drugs': the development of drug resistance. 6 As further explained by McCormick, 7 unlike other existing chemotherapies such as 5-fluorouracil and methotrexate which block enzymes that are indirectly involved in cancer, STI-571 affects a target that directly causes leukemia. Yet, despite this fundamental difference, resistance to STI-571 is depressingly similar to resistance to 5-FU and methotrexate. 7 Every cloud has a silver lining. Although it may sound paradoxical, the rapid development of resistance to STI-571 indicates that this drug is effective and selective. 
The Darwinian selection and STI-571
If STI-571 is truly selective and effective, such an unfortunate characteristic as the development of drug resistance is predictable. In this respect, STI-571 must be 'worse' than conventional drugs: the resistance to STI-571 must develop faster and be more uniform than the resistance to conventional (and less selective) drugs. In light of the Darwinian selection, by killing drug-sensitive cells, a drug selects for resistant clones ( Figure 1 ). This is exactly what a selective therapy does by definition ( Figure 1 ). Simultaneously, a drug also selects for genetically unstable cells (cells with high mutation rate due to defects of DNA repair). 8 Like any mutation, mutations that confirm resistance (eg mutation in Bcr-Abl) predominantly occur in genetically unstable cells. As shown in Figure 1 , selection for such mutations automatically selects for genetically unstable cells. In other words, by killing drug-sensitive cells, a drug selects for resistant cells which are genetically unstable.
Three requirements for development of resistance to highly effective drugs
In order to be selected, resistance-confirming mutations must first occur. Will a mutation repertoire always provide resistant variants? There are three factors that determine development of the necessary resistance to highly selective drugs: (1) genetic instability of tumor cells; (2) number of self-repopulating tumor cells; and (3) the compatibility of mechanisms of resistance with cell functions.
Figure 1
Effective therapy selects for both resistance-confirming mutation and genetic instability. Resistance-confirming (adaptive) mutations occur in genetically unstable cells.
Genetic instability (a mutation rate)
Like any mutations, resistance-confirming mutations occur more often in genetically unstable cells. Given that genetic instability is a hallmark of cancer, 9 a high mutation rate is (to a certain extent) an inevitable predisposition. Currently, we cannot therapeutically enhance DNA repair to prevent resistance-bearing mutations.
As shown in Figure 1 , anticancer drugs select for cells with a high mutation rate. 8 This suggests that prior chemotherapy, which selects for genetic instability, increases the chances of relapse following STI-571 therapy. This may explain why pretreated patients relapse faster. On the other hand, one can expect that STI-571-relapsed leukemia will be even more genetically unstable. These predictions are testable.
Number of tumor cells (tumor burden)
Obviously, more cells can produce more mutations and a wider mutation repertoire. Therefore, a high number of proliferating tumor cells, or high tumor burden, will accelerate the development of drug resistance. Patients with a high tumor burden will be more likely to relapse. This predicts that patients in the early stages of leukemia or in remission caused by chemotherapy may benefit from STI-571 most. In contrast to genetic instability, tumor burden can be decreased by chemotherapy, radiotherapy or surgically.
Why do patients in blast crisis relapse?
Certainly, progression to blast crisis can be accompanied by acquiring resistance due to loss of tumor suppressors and activation of oncogenes, including Bcr-Abl amplifications. In fact, only 55% of patients with a myeloid blast crisis responded. 4 However, if blast crisis undergoes remissions, this indicates sensitivity to therapy. Furthermore, it has been shown that cells in blast crisis and in chronic phase are equally sensitive to STI-571 in vitro. 10 So why do patients in blast crisis have relapsed leukemia after an initial response?
A high number of proliferating blast cells and increased genetic instability can explain why resistance develops more easily in blast crisis than in chronic phase. (1) There is a relatively low number of blast repopulating cells in chronic phase. (2) Genetic instability is also higher in blast crisis. In fact, in the blast phase, more than 60% of patients show additional cytogenetic changes, consistent with genome instability.
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Genetic instability universally rises during tumor progression. 9 Like anticancer drugs, barriers in tumor progression select for additional mutations, and these mutations happen to occur in genetically unstable cells (Figure 2) . Therefore, the mutation rate rises during tumor progression 8 (from CML to blast crisis). Accordingly, while sensitivity to a drug determines response and remission, it may not predict relapse. Genetic instability and initial tumor burden may determine relapse.
Mechanism of resistance
Different and numerous potential mechanisms of resistance increase the probability of its development. Expression of drug pumps, mutations or amplifications in drug targets, and inhibition of downstream apoptotic pathways can confer drug resistance. In vitro, amplification of Bcr-Abl, 12 ,13 an increase
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Figure 2
Tumor progression selects for genetic instability. Tumorpromoting (adaptive) mutations occur in genetically unstable cells.
in the Bcr-Abl protein expression, 14 expression of Pgp, 13 and activation of downstream signaling pathways 15 can confer drug resistance. Amplifications of Bcr-Abl, duplicated and inverted Ph chromosome were found in relapse. 5, [16] [17] [18] Given that leukemogenic effects of Bcr-Abl are proportional to its levels, 19 development of STI-571 resistance due to Bcr-Abl overexpression may further drive leukemogenesis. As reported by Gorre et al, 5 amplification of Bcr-Abl and the mutation, threonine to isoleucine substitution at position 315 of c-Abl (T315I), lead to resistance in most patients. In other clinical trials by Hochhaus, Barthe et al, however, this particular mutation was not found, although Glu to Lys substitution at position 255 of Abl (E255K) was found in two patients. 18 What might determine the difference? As noted by Gorre et al, the patients, who later acquired T315 mutation, obtained complete remissions. This indicates that most Bcr-Abl cells were killed, and perhaps one single cell with the utmost resistanceconfirming mutation (eg T315I) has produced a resistant clone. The relapsed resistant population is relatively uniform (Figure 3a) , as a benchmark of highly selective and effective
Figure 3
Resistance profile of leukemia cell population in relapse. (a) Following complete remission; (b) following partial remission.
therapy. The patients with partial response will have a high proportion of sensitive cells, as well as a diverse population of resistant cells (Figure 3b) .
Finally, the mechanism of resistance must be compatible with cell functions. It seems that two mutations are emerging: T315I and E255K. By combining STI-571 with drugs that target Bcr-Abl by a different mechanism, we may decrease the chance for leukemia cells to acquire resistance. Several drugs that hit different parts of the same target might be ideal. 7 For example, geldanamycin, an Hsp90-active drug, targets Bcr-Abl for degradation and depleted cells from Bcr-Abl thus causing apoptosis and rendering cells sensitive to chemotherapy. 20, 21 The kinase may not tolerate additional alterations. 7 Mutations may never provide such a drug-resistant Bcr-Abl variant. Despite a need for resistance, cells may not produce the necessary mechanism. Then, therapy will force leukemia cells to die. As put by Richard Dawkins, in his discussion of the evolution of species by a means of natural selection, 'it is not true that whatever selection might in principle favor, mutation will always come up with the necessary variation. No animal breathes fire out of its nostrils like a dragon, for instance'. 22 
